Peplobio Ltd

Peplobio Ltd, based in Milton Keynes, UK, is a small, active company founded four years ago. With ten employees and £27,384 in assets, it operates from a virtual address – registered at a location shared by 79 other companies – and is led by one director and two owners. The company has a respectable Google rating of 4.0 based on 80 reviews. Peplobio is an irregular importer of pharmaceutical products, with just two months of import activity recorded, the last in March 2023.

The company’s website reveals it’s a contract research organisation (CRO) specializing in clinical diagnostics and immune monitoring services. It offers a range of services, from precision medicine and immunoassay development to clinical trial management and genomic testing. Notably, Peplobio has developed a proprietary assay for microclot detection, targeting chronic diseases like Long COVID and Lyme disease – a growing area of research. It even has a partnership hub offering services like digital marketing and account management.

Financially, Peplobio Ltd shows concerning trends. Current assets have plummeted 77%, dropping to £27,000, while net assets have suffered an even steeper decline, falling 74% to -£250,000. Cash reserves have evaporated, decreasing 97% to a mere £2,500. Bank borrowings have increased, and creditors have ballooned by 87%, reaching £160,000. The company’s small size (meeting two of three criteria for a small company) does allow for flexibility, but the sharp decline in equity and cash is a significant worry. The fact that no auditor is mentioned suggests the accounts are unaudited, relying on director-reported data.

It appears Peplobio is burning through money, despite its growing research focus and proprietary assay. Whether it can secure funding or generate enough revenue to reverse this trend remains to be seen.

Registered in England/Wales under the registration number 13181011, with a registered address at MK15 0DU, England, Milton Keynes, 19 Diamond Court Opal Drive, Fox Milne.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.